Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238110 | 1.00 | SIGMAR1 (0.53) | SIGMAR1KCNH2ALOX15MEN1ALDH1A1 | |
| SCHEMBL238868 | 0.99 | SIGMAR1 (0.54) | SIGMAR1KCNH2ALOX15MEN1ALDH1A1 | |
| Oxalic Acid SCHEMBL235579 | 0.94 | SIGMAR1 (0.48) | SIGMAR1KCNH2ALDH1A1POLB | |
| Oxalic Acid SCHEMBL235551 | 0.94 | SIGMAR1 (0.48) | SIGMAR1KCNH2ALDH1A1POLB | |
| Oxalic Acid SCHEMBL238506 | 0.93 | SIGMAR1 (0.49) | SIGMAR1KCNH2ALDH1A1POLBHTT | |
| SCHEMBL238331 | 0.92 | SIGMAR1 (0.56) | SIGMAR1KCNH2 | |
| SCHEMBL240126 | 0.92 | SIGMAR1 (0.54) | SIGMAR1KCNH2 | |
| SCHEMBL236046 | 0.91 | SIGMAR1 (0.55) | SIGMAR1KCNH2 | |
| SCHEMBL235600 | 0.91 | SIGMAR1 (0.55) | SIGMAR1KCNH2 | |
| SCHEMBL239393 | 0.90 | SIGMAR1 (0.54) | SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097394-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-12-25 | — | — | EP | claimed |
| US-8349878-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-01-08 | — | — | US | claimed |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-05 | — | — | US | claimed |
| EP-2097394-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-8039497-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885KCNH2 2052/4885ALOX15 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.